Viking Therapeutics, Inc. (VKTX)
32.92
+0.14
(+0.43%)
USD |
NASDAQ |
Sep 01, 11:12
Viking Therapeutics Cash from Operations (TTM) : -418.44M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -418.44M |
| March 31, 2026 | -340.33M |
| December 31, 2025 | -278.68M |
| September 30, 2025 | -224.58M |
| June 30, 2025 | -152.54M |
| March 31, 2025 | -133.99M |
| December 31, 2024 | -87.79M |
| September 30, 2024 | -74.25M |
| June 30, 2024 | -71.94M |
| March 31, 2024 | -54.87M |
| December 31, 2023 | -73.38M |
| September 30, 2023 | -66.66M |
| June 30, 2023 | -60.50M |
| March 31, 2023 | -62.51M |
| December 31, 2022 | -48.40M |
| September 30, 2022 | -49.82M |
| June 30, 2022 | -47.25M |
| March 31, 2022 | -47.24M |
| December 31, 2021 | -47.59M |
| September 30, 2021 | -40.72M |
| June 30, 2021 | -35.12M |
| March 31, 2021 | -28.35M |
| Date | Value |
|---|---|
| December 31, 2020 | -21.78M |
| September 30, 2020 | -28.03M |
| June 30, 2020 | -26.11M |
| March 31, 2020 | -25.90M |
| December 31, 2019 | -24.75M |
| September 30, 2019 | -15.69M |
| June 30, 2019 | -17.79M |
| March 31, 2019 | -16.60M |
| December 31, 2018 | -18.76M |
| September 30, 2018 | -20.02M |
| June 30, 2018 | -17.85M |
| March 31, 2018 | -16.78M |
| December 31, 2017 | -14.76M |
| September 30, 2017 | -13.27M |
| June 30, 2017 | -12.60M |
| March 31, 2017 | -11.62M |
| December 31, 2016 | -11.07M |
| September 30, 2016 | -11.91M |
| June 30, 2016 | -12.65M |
| March 31, 2016 | -11.05M |
| December 31, 2015 | -8.732M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 4.293B |
| Eli Lilly & Co. | 28.08B |
| Regeneron Pharmaceuticals, Inc. | 4.681B |
| Skye Bioscience, Inc. | -38.81M |
| Eledon Pharmaceuticals, Inc. | -73.86M |